95 related articles for article (PubMed ID: 11707751)
1. Cardiovascular safety of COX-2 inhibitors.
Med Lett Drugs Ther; 2001 Nov; 43(1118):99-100. PubMed ID: 11707751
[No Abstract] [Full Text] [Related]
2. How safe are your prescription pills?
Gorman C
Time; 2001 Sep; 158(9):50-1. PubMed ID: 11550614
[No Abstract] [Full Text] [Related]
3. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
[No Abstract] [Full Text] [Related]
4. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors.
Strand V; Hochberg MC
Arthritis Rheum; 2002 Aug; 47(4):349-55. PubMed ID: 12209478
[No Abstract] [Full Text] [Related]
5. Differences between COX-2-specific inhibitors: clinical and economic implications.
Sonnenblick EH
Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
[No Abstract] [Full Text] [Related]
6. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten WW; Reiter S;
Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
[No Abstract] [Full Text] [Related]
7. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith ER
Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
[No Abstract] [Full Text] [Related]
8. COX-2 inhibitors: no pain, no heart gain?
Harv Heart Lett; 2001 Dec; 12(4):2-4. PubMed ID: 11751079
[No Abstract] [Full Text] [Related]
9. [COX-2 inhibitors--one step forward and two steps back].
Evensen S; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
[TBL] [Abstract][Full Text] [Related]
10. Why don't we initiate more large simple randomized controlled trials?
Wright JM
CMAJ; 2003 Nov; 169(11):1170-1. PubMed ID: 14638653
[No Abstract] [Full Text] [Related]
11. Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Kelkar PS; Butterfield JH; Teaford HG
J Rheumatol; 2001 Nov; 28(11):2553-4. PubMed ID: 11708434
[TBL] [Abstract][Full Text] [Related]
12. Is concern about cardiovascular events with the new coxib class of drugs justified?
Schnitzer TJ
Medscape Womens Health; 2001 Oct; 6(5):8. PubMed ID: 11698930
[No Abstract] [Full Text] [Related]
13. Institutional review boards must conduct safety review.
Maloney DM
Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
[No Abstract] [Full Text] [Related]
14. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Umar A; Boisseau M; Yusup A; Upur H; Bégaud B; Moore N
Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
[TBL] [Abstract][Full Text] [Related]
15. Does the dose make the poison?
Harris RE
Science; 2005 Apr; 308(5719):203. PubMed ID: 15821073
[No Abstract] [Full Text] [Related]
16. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Couzin J
Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
[No Abstract] [Full Text] [Related]
17. Painful lessons.
Nat Struct Mol Biol; 2005 Mar; 12(3):205. PubMed ID: 15744317
[No Abstract] [Full Text] [Related]
18. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
19. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
[No Abstract] [Full Text] [Related]
20. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
